Mainz Net Income From Continuing Ops from 2010 to 2024

MYNZ Stock  USD 0.22  0.04  15.38%   
Mainz Biomed Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss is likely to outpace its year average in 2024. During the period from 2010 to 2024, Mainz Biomed Net Loss regression line of annual values had significance of  0 and arithmetic mean of (6,634,440). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-26.3 M
Current Value
-25 M
Quarterly Volatility
10.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mainz Biomed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mainz Biomed's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 1.1 M or Interest Expense of 419.9 K, as well as many indicators such as Price To Sales Ratio of 19.99, Dividend Yield of 0.0 or PTB Ratio of 6.09. Mainz financial statements analysis is a perfect complement when working with Mainz Biomed Valuation or Volatility modules.
  
Check out the analysis of Mainz Biomed Correlation against competitors.

Latest Mainz Biomed's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Mainz Biomed BV over the last few years. It is Mainz Biomed's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mainz Biomed's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Mainz Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(6,634,440)
Coefficient Of Variation(155.91)
Mean Deviation8,376,187
Median(957,055)
Standard Deviation10,343,555
Sample Variance107T
Range25.8M
R-Value(0.76)
Mean Square Error49.5T
R-Squared0.57
Significance0
Slope(1,747,116)
Total Sum of Squares1497.8T

Mainz Net Income From Continuing Ops History

2024-25 M
2023-26.3 M
2022-26.4 M
2021-11.7 M
2020-586.9 K

About Mainz Biomed Financial Statements

Mainz Biomed investors use historical fundamental indicators, such as Mainz Biomed's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Mainz Biomed. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-26.3 M-25 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Mainz Stock Analysis

When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.